Literature DB >> 2910425

Effect of cumulative courses of intraarterial cis-diamminedichloroplatin-II on the primary tumor in osteosarcoma.

N Jaffe1, A K Raymond, A Ayala, C H Carrasco, S Wallace, R Robertson, M Griffiths, Y M Wang.   

Abstract

Preoperative chemotherapy with intraarterial cis-diamminedichloroplatin-II (CDP) and mannitol diuresis was administered to the primary tumor in 42 patients with osteosarcoma. The dose was 150 mg/m2 and more than 90% of the infusions were administered during a 2-week period. On occasion this period was extended to 3 weeks because of temporary renal insufficiency or logistical circumstances. Definitive surgical specimens were prepared by means of an arteriogram-directed plane of dissection with mapping and random sections. Histologically, tumor destruction was evaluated in terms of necrosis, inflammatory response, and fibrovascular regeneration. Quantification of the percent of tumor necrosis was as follows: less than 40% (consistent with spontaneous necrosis and/or no chemotherapy effect); 40% to 60% (possible chemotherapy effect); 60% to 90% (chemotherapy effect--partial response); and 90% to 100% (complete response). Therapeutic efficacy also was correlated with the number of CDP courses (one to three, four to five, and six to seven) and tumor subtype. Significant therapeutic effect (greater than 60% destruction) was observed with four or more CDP courses (one of nine tumors [one to three courses] versus 26 of 33 tumors [four to seven courses] [P = 0.01]). More than 60% of the tumor destruction was observed in the following subtypes: osteoblastic (22 of 28), fibroblastic (three of six), and telangiectatic (two of five). These data demonstrate that four or more courses of intraarterial CDP are required to achieve optimum effects and that osteoblastic osteosarcoma is highly responsive.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2910425     DOI: 10.1002/1097-0142(19890101)63:1<63::aid-cncr2820630110>3.0.co;2-o

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Amputation and dexniguldipine as treatment for canine appendicular osteosarcoma.

Authors:  K A Hahn; A M Legendre; H M Schuller
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

Review 2.  Strategies for the targeted delivery of therapeutics for osteosarcoma.

Authors:  Dennis P M Hughes
Journal:  Expert Opin Drug Deliv       Date:  2009-12       Impact factor: 6.648

3.  Intraarterial chemotherapy for extremity osteosarcoma and MFH in adults.

Authors:  Ronald R Hugate; Ross M Wilkins; Cynthia M Kelly; Walt Madsen; Ioana Hinshaw; Anne B Camozzi
Journal:  Clin Orthop Relat Res       Date:  2008-04-25       Impact factor: 4.176

4.  The Current and Future Therapies for Human Osteosarcoma.

Authors:  Joseph D Lamplot; Sahitya Denduluri; Jiaqiang Qin; Ruidong Li; Xing Liu; Hongyu Zhang; Xiang Chen; Ning Wang; Abdullah Pratt; Wei Shui; Xiaoji Luo; Guoxin Nan; Zhong-Liang Deng; Jinyong Luo; Rex C Haydon; Tong-Chuan He; Hue H Luu
Journal:  Curr Cancer Ther Rev       Date:  2013-02

5.  Gain and loss from transcatheter intra-arterial limb infusion of cisplatin for extremity osteosarcoma: a retrospective study of 99 cases in the past six years.

Authors:  Lu Xie; Jie Xu; Sen Dong; Jian Gao; Xiaodong Tang; Taiqiang Yan; Rongli Yang; Wei Guo
Journal:  Cancer Manag Res       Date:  2019-07-30       Impact factor: 3.989

6.  Evaluation of intraarterial and intravenous cisplatin chemotherapy in the treatment of metastatic osteosarcoma using an orthotopic xenograft mouse model.

Authors:  Bernhard Robl; Sander Martijn Botter; Giovanni Pellegrini; Olga Neklyudova; Bruno Fuchs
Journal:  J Exp Clin Cancer Res       Date:  2016-07-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.